Oric Pharmaceuticals, Inc. (ORIC) is a clinical-stage biopharmaceutical company that sets new benchmarks in the world of cancer treatment. Established in 2014, and based in South San Francisco, California, the company is esteemed for its dedication to overcoming treatment resistance in cancer patients.
Oric Pharmaceuticals upholds a mission to "discovery the undiscovered," which involves extensively researching and developing novel treatments that can strategically counteract the mechanisms by which cancers fight back against treatment. They believe that by discovering these resistance mechanisms, they can create therapies that limit the effectiveness of tumors and overcome resistance to see effective results in treating cancer.
The company has an impressive pipeline of product candidates. Its leading candidate is ORIC-101, which demonstrates important functions in multiple resistance mechanisms to various cancer therapies. This small molecule glucocorticoid receptor antagonist is being developed for solid tumors resistant to checkpoint inhibition and metastatic prostate cancer. Beyond ORIC-101, there are also three other drugs at different stages of development set to cater to different types of cancer.
ORIC's research, backed by high scientific rigor, targets the significant needs of patients who do not respond, or no longer respond to current cancer therapies. Their staff consists of scientific pioneers and experienced drug developers who continue to augment the company's drug pipeline.
In addition to its leading innovations in cancer treatment, ORIC is also known for its strong collaborations with noted biotech and pharma companies. Over the years, the company has managed to secure persistent funding from leading venture capital firms, industry partners, public investors and non-profit partners.
Interestingly, the term ORIC stands for 'Overcoming Resistance In Cancer,' reflecting the company's relentless determination and commitment to fight cancer. This also underscores the company's ethos in continuously seeking ways to outsmart cancer and its adaptability to resist treatment. They expose the cancer's playbook, target treatment, and help more people overcome the disease.
Oric Pharmaceuticals went public in April 2020, joining the NASDAQ under the ticker symbol "ORIC." Despite the challenges of the Covid-19 pandemic, the company has continued to make incredible strides in its quest to bring novel, effective cancer treatments to patients. Its relentless pursuit of pioneering techniques to overcome resistance distinguishes ORIC Pharmaceuticals, Inc. as a beacon of hope in the cancer treatment landscape.